CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session. ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

OptionMetrics and CRSP provide increased integration of U.S. equities and options data for use in academic research ...